耶鲁布朗强迫量表 (Y-BOCS) 评分：有低质量证据表明，认知行为疗法能够显著降低 Y-BOCS 评分。[51]Volpato Cordioli A, Heldt E, Braga Bochi D, et al. Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial. Psychother Psychosom. 2003;72:211-216.http://www.ncbi.nlm.nih.gov/pubmed/12792126?tool=bestpractice.com[52]Vogel PA, Stiles TC, Gotestam KG. Adding cognitive therapy elements to exposure therapy for obsessive compulsive disorder: a controlled study. Behav Cogn Psychother. 2004;32:275-290.
系统评价或者受试者＞200名的随机对照临床试验（RCT）。
耶鲁布朗强迫量表 (Y-BOCS) 评分：有低质量证据表明，认知行为疗法能够显著降低 Y-BOCS 评分。[51]Volpato Cordioli A, Heldt E, Braga Bochi D, et al. Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial. Psychother Psychosom. 2003;72:211-216.http://www.ncbi.nlm.nih.gov/pubmed/12792126?tool=bestpractice.com[52]Vogel PA, Stiles TC, Gotestam KG. Adding cognitive therapy elements to exposure therapy for obsessive compulsive disorder: a controlled study. Behav Cogn Psychother. 2004;32:275-290.
改善症状：有低质量证据表明，与安慰剂相比，选择性或非选择性 5-羟色胺再摄取抑制剂西酞普兰、氯米帕明、氟西汀、氟伏沙明和帕罗西汀能显著改善症状。[53]Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995;166:424-443.http://www.ncbi.nlm.nih.gov/pubmed/7795913?tool=bestpractice.com[54]Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002;22:309-317.http://www.ncbi.nlm.nih.gov/pubmed/12006902?tool=bestpractice.com
系统评价或者受试者＞200名的随机对照临床试验（RCT）。
改善症状：有低质量证据表明，与安慰剂相比，选择性或非选择性 5-羟色胺再摄取抑制剂西酞普兰、氯米帕明、氟西汀、氟伏沙明和帕罗西汀能显著改善症状。[53]Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995;166:424-443.http://www.ncbi.nlm.nih.gov/pubmed/7795913?tool=bestpractice.com[54]Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002;22:309-317.http://www.ncbi.nlm.nih.gov/pubmed/12006902?tool=bestpractice.com
耶鲁-布朗强迫量表、临床疗效总评量表 (clinical global impression, CGI) 和临床评估的改善：有低质量证据表明， 5-羟色胺再摄取抑制剂（SSRI 和氯米帕明）加用抗精神病药物可以改善单用 5-羟色胺再摄取抑制剂无效患者的症状。[82]Erzegovesi S, Guglielmo E, Siliprandi F, et al. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005;15:69-74.http://www.ncbi.nlm.nih.gov/pubmed/15572275?tool=bestpractice.com[83]McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794-801.http://archpsyc.jamanetwork.com/article.aspx?articleid=481641http://www.ncbi.nlm.nih.gov/pubmed/10920469?tool=bestpractice.com[84]Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17:115-119.http://www.ncbi.nlm.nih.gov/pubmed/11981352?tool=bestpractice.com[85]Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004;55:553-555.http://www.ncbi.nlm.nih.gov/pubmed/15023585?tool=bestpractice.com[86]McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302-308.http://www.ncbi.nlm.nih.gov/pubmed/8161290?tool=bestpractice.com
系统评价或者受试者＞200名的随机对照临床试验（RCT）。
耶鲁-布朗强迫量表、临床疗效总评量表 (clinical global impression, CGI) 和临床评估的改善：有低质量证据表明， 5-羟色胺再摄取抑制剂（SSRI 和氯米帕明）加用抗精神病药物可以改善单用 5-羟色胺再摄取抑制剂无效患者的症状。[82]Erzegovesi S, Guglielmo E, Siliprandi F, et al. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005;15:69-74.http://www.ncbi.nlm.nih.gov/pubmed/15572275?tool=bestpractice.com[83]McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794-801.http://archpsyc.jamanetwork.com/article.aspx?articleid=481641http://www.ncbi.nlm.nih.gov/pubmed/10920469?tool=bestpractice.com[84]Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17:115-119.http://www.ncbi.nlm.nih.gov/pubmed/11981352?tool=bestpractice.com[85]Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004;55:553-555.http://www.ncbi.nlm.nih.gov/pubmed/15023585?tool=bestpractice.com[86]McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302-308.http://www.ncbi.nlm.nih.gov/pubmed/8161290?tool=bestpractice.com
